Harmony Biosciences
HRMY
183 hedge funds and large institutions have $2.29B invested in Harmony Biosciences in 2022 Q2 according to their latest regulatory filings, with 30 funds opening new positions, 72 increasing their positions, 62 reducing their positions, and 25 closing their positions.
1,133% more call options, than puts
Call options by funds: $3.6M | Put options by funds: $292K
20% more first-time investments, than exits
New positions opened: 30 | Existing positions closed: 25
16% more repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 62
2.33% more ownership
Funds ownership: 78.38% → 80.7% (+2.3%)
4% more capital invested
Capital invested by funds: $2.21B → $2.29B (+$85.8M)
1% more funds holding
Funds holding: 182 → 183 (+1)
30% less funds holding in top 10
Funds holding in top 10: 10 → 7 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$26M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$23.8M |
| 3 |
PA
Perceptive Advisors
New York
|
+$18.5M |
| 4 |
NPIC
Neumeier Poma Investment Counsel
Carmel,
California
|
+$17.4M |
| 5 |
LCG
Lisanti Capital Growth
New York
|
+$13.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NP
Newlight Partners
New York
|
-$29.3M |
| 2 |
VC
Vivo Capital
Palo Alto,
California
|
-$21.4M |
| 3 |
ACM
Aisling Capital Management
New York
|
-$16.7M |
| 4 |
IBT
International Biotechnology Trust
London,
United Kingdom
|
-$8.76M |
| 5 |
Two Sigma Investments
New York
|
-$8.69M |
HRMY Hedge Fund Activity: Q2 2022 in Review
183 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Harmony Biosciences (HRMY) for Q2 2022, worth a combined $2.29B — up 3.9% from $2.21B a quarter earlier.
Buyers outnumbered sellers: 30 funds opened new HRMY positions and 25 closed out — a net gain of 5 holders — while 72 added to existing stakes and 62 trimmed.
The largest buyer was Bellevue Group, adding an estimated $26M. The largest seller was Newlight Partners, cutting an estimated $29.3M.
- 183 institutional investors held Harmony Biosciences (HRMY) as of Q2 2022, up from 182 in Q1 2022.
- Funds reported $2.29B of Harmony Biosciences stock for Q2 2022, up 3.9% quarter-over-quarter.
- 30 funds opened new Harmony Biosciences positions in Q2 2022 and 25 closed out, a net change of +5 holders.
- The largest Harmony Biosciences buyer in Q2 2022 was Bellevue Group, an estimated $26M added.
- The largest Harmony Biosciences seller in Q2 2022 was Newlight Partners, an estimated $29.3M sold.
Based on aggregated 13F filings for Q2 2022.